A few days ago, a friend asked if I’d made any New Year’s resolutions. “No,” I replied, shrugging. Then I changed my mind and answered “yes.” Seeing her bewildered expression upon my contradictory response, I knew I had to explain. I used to enjoy the tradition of making resolutions every…

Neurosense Therapeutics has entered a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its oral therapy for amyotrophic lateral sclerosis (ALS). The binding term sheet, a preliminary document outlining the terms and conditions of a potential agreement between the…

My husband, Todd, was diagnosed with ALS in June 2010. That winter, Todd and I, along with our 4-year-old daughter and 1-year-old son, visited my parents in Michigan’s Upper Peninsula. My dad had plowed snow into high banks, and on one large pile next to the house, he had…

In the field next to our home, a stand of more than 100 Fraser firs provide boughs for my wreath-making operation. It’s a good seasonal gig for me because it’s flexible. Since I take care of my husband, Todd, who is paralyzed due to ALS, I can’t work outside…

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to CNM-Au8 to treat amyotrophic lateral sclerosis (ALS), based on data from clinical trials and ongoing expanded access programs. The therapy’s developer, Clene, said it will put together an…

The University Health Network (UHN) in Toronto was selected as the first site in Canada to be part of a clinical trial testing Neuralink‘s brain-computer interface (BCI) in people unable to move their limbs due to amyotrophic lateral sclerosis (ALS) or spinal cord injury. The start of patient…

Widetrial, an integrated service and technology platform, is coming on board to support an expanded access program (EAP) that will provide the investigational therapy MN-166 (ibudilast) to amyotrophic lateral sclerosis (ALS) patients who aren’t eligible for clinical trials. The program is funded under a $22 million federal…

I remember the first time my late husband, Jeff, fell as a result of ALS. Falls can be common with the disease, but I was still shocked each time one happened. When Jeff fell, it laid bare how ill qualified I felt to care for him, even while taking…

I’m a do-it-yourself kind of gal. This has served my husband, Todd, and I well over the last 14 years as I’ve been his primary caregiver. We do not have an ALS clinic near our home, and our local neurologist moved away years ago, so we don’t have medical…

The European Medicines Agency (EMA) has recommended that monepantel, now named NUZ-001, be granted orphan medicinal product designation to treat amyotrophic lateral sclerosis (ALS). The positive opinion will be reviewed by the European Commission, which is expected to issue a final decision in December. If granted, the designation will provide…